Journal of Antimicrobial Chemotherapy
-
Publication Venue For
- Critical role of the RpoE stress response pathway in polymyxin resistance of Escherichia coli.. 78:732-746. 2023
- Determination of plasma protein binding of dalbavancin.. 77:1899-1902. 2022
- Successful treatment of cutaneous Acanthamoeba castellanii infection with miltefosine in a patient with chronic lymphocytic leukaemia on ibrutinib.. 77:539-541. 2022
- Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load.. 75:3510-3516. 2020
- Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model.. 75:2622-2632. 2020
- Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals.. 75:221-228. 2020
- Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone.. 74:228-233. 2019
- Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants.. 73:3482-3487. 2018
- Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.. 73:2112-2119. 2018
- Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure.. 73:vi50-vi58. 2018
- Metrics to assess the quantity of antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure.. 73:vi59-vi66. 2018
- Quality indicators assessing antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure.. 73:vi40-vi49. 2018
- Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure.. 73:vi30-vi39. 2018
- Tolerability profile of the current antifungal armoury.. 73:i26-i32. 2018
- The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).. 71:ii31-ii36. 2016
- High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.. 71:2874-2882. 2016
- Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study.. 71:2938-2944. 2016
- Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.. 71:2234-2240. 2016
- Intravenous amoxicillin/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial.. 71:2022-2030. 2016
- High prevalence of PI resistance in patients failing second-line ART in Vietnam.. 71:762-774. 2016
- Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species.. 70:1408-1411. 2015
- Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.. 70:1203-1211. 2015
- Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.. 69:1119-1126. 2014
- Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.. 67:1246-1249. 2012
- The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.. 67:715-722. 2012
- CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.. 65 Suppl 4:iv41-iv51. 2010
- CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.. 65 Suppl 4:iv53-iv65. 2010
- Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.. 65:2063-2069. 2010
- Echinocandin pharmacodynamics: review and clinical implications.. 65:1108-1118. 2010
- Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.. 65:1094-1099. 2010
- The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS.. 63:636-640. 2009
- Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.. 62:1413-1421. 2008
- Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment.. 62:1386-1391. 2008
- Anti-gene padlocks eliminate Escherichia coli based on their genotype.. 61:262-272. 2008
- Antifungal serum concentration monitoring: an update.. 61:17-25. 2008
- Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.. 61:177-182. 2008